Search
Cellectar Biosciences Inc
CLRBAdd to Watchlist
2.810USD
-0.020-0.71%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
11.91MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.71%
5 Days
+11.51%
1 Month
+2.18%
6 Months
-19.02%
Year to Date
-4.75%
1 Year
-41.46%
Key Figures
2.850Open
3.020High
26.24KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.62%Turnover Ratio
2.830Prev. Close
2.770Low
39.16KTurnover
LossP/E Static
1.49P/B
0.00%Div Yield TTM
-153.46%ROA
20.59552wk High
0.30Volume Ratio
-44.58MNet Profit
4.24MShares
-5.3883EPS TTM
0.50Beta
-395.20%ROE
2.43052wk Low
8.83%Amplitude
--Gross Margin
11.91MMarket Cap
0.58Reward/Risk
5.03%Risk Rate
TradingKey Stock Score of Cellectar Biosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Cellectar Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 98 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cellectar Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Cellectar Biosciences Inc Highlights
StrengthsRisks
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Undervalued
The company’s latest PE is -0.52, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 366.56K shares, decreasing 44.16% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.47.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
10.333
Target Price
+265.14%
Upside Space
Cellectar Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cellectar Biosciences Inc Info
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Ticker SymbolCLRB
CompanyCellectar Biosciences Inc
CEOCaruso (James V)
Websitehttps://www.cellectar.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Cellectar Biosciences Inc (CLRB)?
The current price of Cellectar Biosciences Inc (CLRB) is 2.81.
What is the symbol of Cellectar Biosciences Inc?
The ticker symbol of Cellectar Biosciences Inc is CLRB.
What is the 52-week high of Cellectar Biosciences Inc?
The 52-week high of Cellectar Biosciences Inc is 20.59.
What is the 52-week low of Cellectar Biosciences Inc?
The 52-week low of Cellectar Biosciences Inc is 2.43.
What is the market capitalization of Cellectar Biosciences Inc?
The market capitalization of Cellectar Biosciences Inc is 11.91M.
Is Cellectar Biosciences Inc (CLRB) currently rated as Buy, Hold, or Sell?
According to analysts, Cellectar Biosciences Inc (CLRB) has an overall rating of Buy, with a price target of 10.33.
What is the Earnings Per Share (EPS TTM) of Cellectar Biosciences Inc (CLRB)?
The Earnings Per Share (EPS TTM) of Cellectar Biosciences Inc (CLRB) is -8.35.